227 search results for: Burden of Disease
Disease Modification Concepts in AD
Dr. Ramien explores the concept of disease modification in AD focusing on disease control, and the prevention or slowing of development of atopic comorbidities.
Bullous Pemphigoid: Exploring New Frontiers
Highlights from the ADVENT educational symposium at EADV 2024 discussing the current understanding of the science and treatment landscape in bullous pemphigoid (BP).
ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD
Professor Mona Bafadhel presents a comprehensive overview of type 2 inflammation in COPD, exploring its underlying mechanisms, clinical manifestations, and implications for patient outcomes.
ADVENT On Air | Best Practice for CSU - Perspectives from Allergy and Dermatology
Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria (CSU). They offer practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients.
ERS 2024 | What Do We Know About IL-33 Genetics?
Dr. Stephanie Christenson examines the genetic and environmental factors influencing IL-33 expression and activity in COPD, highlighting the complex interplay between genetics, smoking, and disease pathogenesis.
Exploring the Potential Disease-Modifying Approaches in AD
Explore the concept of disease modification in atopic dermatitis through this interactive infographic, which highlights potential considerations such as optimal sustained disease control, subclinical inflammation, the pathophysiology of AD, and atopic/non-atopic comorbidities.
Coughing, Choking, Wheezing, Itching, Sneezing: Understanding the Connection Between Atopic Diseases Through a Case-Based Panel of Expert Nurse Practitioners
Join leading experts Miguel Lanz, Lakshi Aldredge, Angela Bretton, and Hilary Ugras in an engaging case-based discussion that explores the interconnected nature of chronic underlying type 2 inflammation and its profound impact across multiple diseases.
ADVENT in Orlando, 2025
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Join experts Mario Castro, Nicola Hanania, and Stephanie Christenson for an educational symposium on the real-world impact of underlying type 2 inflammation on the patient burden of asthma and COPD.
Assessing EoE: Using Endoscopic Features to Assess Disease Status
Expert gastroenterologist Dr. Ikuo Hirano highlights the endoscopic features in EoE and reviews the EREFS scoring system to assess disease activity.
Potential for Disease Modification in Atopic Dermatitis
In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Amy Paller, MD explores the possibilities for disease modification in atopic dermatitis.
ERS 2025 | The Knowns and Unknowns in the COPD Landscape
Join Profs. Dave Singh and Klaus Rabe as they examine the clinical relevance of exacerbations, lung function, symptoms, quality of life, and comorbidities in COPD, as well as the evolving concept of disease stability and what that could mean for treatment planning and the future of COPD care.
